Aug25
HIV/AIDS:SWITCHING ARV FOR ADVERSE SIDE EFFECT MAY INCREASE VIRAL LOAD,NEW ARV IS PRESCRIBED IF IT IS ABSOLUTE NECESSARY
Posted by Dr. Dewat Ram Nakipuria on Monday, 25th August 2014
HIV/AIDS:SWITCHING ARV FOR ADVERSE SIDE EFFECT MAY INCREASE VIRAL LOAD,NEW ARV IS PRESCRIBED IF IT IS ABSOLUTE NECESSARY PROF.DRRAM ,HIV/AIDS,SEX DIS.,SEX WEAK.& ABORTION SPECIALIST
profdrram@gmail.com,+917838059592,+919832025033,DELHI –NCR,IND
HIV/ AIDS,CANCER LATEST MEDICINES AVAILABLE AT CHEAP RATE.
FOLLOW ON FACE BOOK:www.facebook.com/ramkumar
FOLLOW ON TWITTER:www.twitter.com/profdrram
As new ARV medicines are coming in market after research,there is growing feeling that if we substitute old with new one better result is found but it is not correct as it has been found in canada that viral load of HIV may increase after starting new therapy.The researchers evaluated the risk for virologic failure in 2807 HIV-infected patients from the CANOC collaboration who initiated antiretroviral therapy from January 2005 to June 2012.CANOC is Canada's largest HIV cohort study. It focuses on evaluating the impact of antiretroviral therapy in people living with HIV across the country.Everyone in the study cohort had achieved virologic suppression, defined as a viral load below 50 copies/mL measured twice, at least 1 month apart. Virologic failure was defined as a viral load above 1000 copies/mL.During the study period, 64% of the patients never switched their antiretroviral regimen, 14% switched regimens once, and 22% switched regimens at least twice. Mean time to first switch was approximately 10 months.
Switching therapy was associated with an increased risk for subsequent virologic failure (adjusted hazard ratio, 2.70), the researchers reporrapy if previous therapy was controlling it nicely so it is advised that we should never try a new therapy or ARV MEDICINE IF CURRENT ONE IS CONTROLLING DISEASE WELL.Change of drug is only done when we get serious side effect which cannot be controlled by easy methods or drugs and we have to stop the drug .
For virologically suppressed HIV patients, a switch in antiretroviral therapy is associated with an increased risk for subsequent virologic failure, Canadian Observational Cohort (CANOC) researchers suggested.